Pemetrexed for Carcinoma
Phase-Based Progress Estimates
Effectiveness
Safety
MD Anderson Cancer Center, Houston, TX
Carcinoma+3 More
Pemetrexed - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This is a Phase 2 open-label, single-arm trial for patients with MTAP-deficient advanced urothelial cancer who had received prior immunotherapy. This is a single site study at the University of Texas MD Anderson Cancer Center. This study will allow patients in second line of treatment for advanced urothelial ca or beyond. All patients must have been previously treated with immune checkpoint inhibitor (ICI) therapy as per current standard of care.
Eligible Conditions
- Carcinoma
- Transitional Cell, Carcinoma
- Metastatic Cancers
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
Year 1
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 and Number of Participants With Complete or Partial Response as their Best Overall Response per RECIST v1.1.
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Pemetrexed · No Placebo Group · Phase 2
Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)Experimental Group · 3 Interventions: Pemetrexed, Zimberelimab, Etrumadenant · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
2014
Completed Phase 3
~5260
Zimberelimab
2018
Completed Phase 1
~50
Etrumadenant
2018
Completed Phase 1
~130
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
2004First Recorded Clinical Trial
74 TrialsResearching Carcinoma
521 CompletedClinical Trials
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,192 Total Patients Enrolled
256 Trials studying Carcinoma
37,378 Patients Enrolled for Carcinoma
Omar Alhalabi, MDPrincipal InvestigatorM.D. Anderson Cancer Center
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You must be at least 18 years of age at the time of screening.
Patients can be considered for second line of therapy or beyond (after ICI with PD-(L)1 agent)
Patients must have measurable disease by RECIST v1.1 and tumors of sufficient sizes for biopsy
You have liver function tests that are normal or only mildly abnormal.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments